Back to Search
Start Over
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
- Source :
-
Breast cancer research : BCR [Breast Cancer Res] 2017 Sep 11; Vol. 19 (1), pp. 107. Date of Electronic Publication: 2017 Sep 11. - Publication Year :
- 2017
-
Abstract
- Background: Poly(ADP-ribose) polymerase inhibitors (PARPi), coupled to a DNA damaging agent is a promising approach to treating triple negative breast cancer (TNBC). However, not all patients respond; we hypothesize that non-response in some patients may be due to insufficient drug penetration. As a first step to testing this hypothesis, we quantified and visualized veliparib and carboplatin penetration in mouse xenograft TNBCs and patient blood samples.<br />Methods: MDA-MB-231, HCC70 or MDA-MB-436 human TNBC cells were implanted in 41 beige SCID mice. Low dose (20 mg/kg) or high dose (60 mg/kg) veliparib was given three times daily for three days, with carboplatin (60 mg/kg) administered twice. In addition, blood samples were analyzed from 19 patients from a phase 1 study of carboplatin + PARPi talazoparib. Veliparib and carboplatin was quantified using liquid chromatography-mass spectrometry (LC-MS). Veliparib tissue penetration was visualized using matrix-assisted laser desorption/ionization mass spectrometric imaging (MALDI-MSI) and platinum adducts (covalent nuclear DNA-binding) were quantified using inductively coupled plasma-mass spectrometry (ICP-MS). Pharmacokinetic modeling and Pearson's correlation were used to explore associations between concentrations in plasma, tumor cells and peripheral blood mononuclear cells (PBMCs).<br />Results: Veliparib penetration in xenograft tumors was highly heterogeneous between and within tumors. Only 35% (CI 95% 26-44%), 74% (40-97%) and 46% (9-37%) of veliparib observed in plasma penetrated into MDA-MB-231, HCC70 and MDA-MB-436 cell-based xenografts, respectively. Within tumors, penetration heterogeneity was larger with the 60 mg/kg compared to the 20 mg/kg dose (RSD 155% versus 255%, P = 0.001). These tumor concentrations were predicted similar to clinical dosing levels, but predicted tumor concentrations were below half maximal concentration values as threshold of response. Xenograft veliparib concentrations correlated positively with platinum adduct formation (R <superscript>2</superscript> = 0.657), but no PARPi-platinum interaction was observed in patients' PBMCs. Platinum adduct formation was significantly higher in five gBRCA carriers (ratio of platinum in DNA in PBMCs/plasma 0.64% (IQR 0.60-1.16%) compared to nine non-carriers (ratio 0.29% (IQR 0.21-0.66%, P < 0.0001).<br />Conclusions: PARPi/platinum tumor penetration can be measured by MALDI-MSI and ICP-MS in PBMCs and fresh frozen, OCT embedded core needle biopsies. Large variability in platinum adduct formation and spatial heterogeneity in veliparib distribution may lead to insufficient drug exposure in select cell populations.
- Subjects :
- Animals
Benzimidazoles chemistry
Carboplatin chemistry
Cell Line, Tumor
Female
Humans
Leukocytes, Mononuclear drug effects
Mice
Penetrance
Poly(ADP-ribose) Polymerase Inhibitors chemistry
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Triple Negative Breast Neoplasms pathology
Xenograft Model Antitumor Assays
Benzimidazoles administration & dosage
Carboplatin administration & dosage
Poly(ADP-ribose) Polymerase Inhibitors administration & dosage
Triple Negative Breast Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1465-542X
- Volume :
- 19
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Breast cancer research : BCR
- Publication Type :
- Academic Journal
- Accession number :
- 28893315
- Full Text :
- https://doi.org/10.1186/s13058-017-0896-4